- Main
Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction
- Zhao, Xin;
- Chen, Haodong;
- Xiao, Dan;
- Yang, Huaxiao;
- Itzhaki, Ilanit;
- Qin, Xulei;
- Chour, Tony;
- Aguirre, Aitor;
- Lehmann, Kim;
- Kim, Youngkyun;
- Shukla, Praveen;
- Holmström, Alexandra;
- Zhang, Joe Z;
- Zhuge, Yan;
- Ndoye, Babacar C;
- Zhao, Mingtao;
- Neofytou, Evgenios;
- Zimmermann, Wolfram-Hubertus;
- Jain, Mohit;
- Wu, Joseph C
- et al.
Published Web Location
https://doi.org/10.1016/j.stemcr.2018.01.002Abstract
Non-human primates (NHPs) can serve as a human-like model to study cell therapy using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). However, whether the efficacy of NHP and human iPSC-CMs is mechanistically similar remains unknown. To examine this, RNU rats received intramyocardial injection of 1 × 107 NHP or human iPSC-CMs or the same number of respective fibroblasts or PBS control (n = 9-14/group) at 4 days after 60-min coronary artery occlusion-reperfusion. Cardiac function and left ventricular remodeling were similarly improved in both iPSC-CM-treated groups. To mimic the ischemic environment in the infarcted heart, both cultured NHP and human iPSC-CMs underwent 24-hr hypoxia in vitro. Both cells and media were collected, and similarities in transcriptomic as well as metabolomic profiles were noted between both groups. In conclusion, both NHP and human iPSC-CMs confer similar cardioprotection in a rodent myocardial infarction model through relatively similar mechanisms via promotion of cell survival, angiogenesis, and inhibition of hypertrophy and fibrosis.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-